Trials / Completed
CompletedNCT01540604
CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- RSPR Pharma AB · Industry
- Sex
- All
- Age
- 2 Years – 11 Years
- Healthy volunteers
- —
Summary
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CRD007 |
Timeline
- First posted
- 2012-02-29
- Last updated
- 2012-10-02
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT01540604. Inclusion in this directory is not an endorsement.